Page 11 - CUAJFeb2023

Help Your MYRBETRIQ ® is the
dispensed
OAB Patients OAB

Fight the Urge medication 2*
across Canada

MYRBETRIQ (mirabegron) is indicated for the treatment
®
of overactive bladder (OAB) with symptoms of urgency,
urgency incontinence and urinary frequency. 1

Covered in 9 out of 10 provinces,
2 5 m g O D
and the NIHB, with special authorization †

Consult the product monograph at https://health-products.canada.ca/dpd-bdpp/index-eng.jsp for important information about:
• Contraindications in patients with severe uncontrolled hypertension (SBP ≥180 mm Hg and/or DBP ≥110 mm Hg) and in
pregnancy
• Relevant warnings and precautions relating to serious adverse events of neoplasm (0.1%, reported in a study with
MYRBETRIQ 50 mg ); serum ALT/AST increase (0.3%, reported in a study with MYRBETRIQ 50 mg ) with/without
®
#
®
#
bilirubin increase and Stevens–Johnson syndrome; risk of cardiovascular effects (dose dependent QTc prolongation,
elevated blood pressure, elevated heart rate); use in patients with clinically signifi cant bladder outlet obstruction, hepatic or
renal impairment, or risk factors for torsade de pointes; use in patients taking medications known to prolong the QT interval
or antimuscarinics for OAB; interaction with CYP2D6 substrates; ophthalmological examinations in patients with glaucoma;
and use during nursing
• Conditions of clinical use, adverse reactions, drug interactions and dosing instructions
The Product Monograph is also available by calling us at 1-888-338-1824.

Consider MYRBETRIQ —the only selective
®
β3 adrenoceptor agonist indicated in OAB *

References:

1. MYRBETRIQ ® Product Monograph. Astellas Pharma Canada Inc. June 2, 2016.
2. IQVIA. Canadian CompuScript Data. August 2021.
3. RAMQ (offi cial mark of the Régie de l’assurance maladie du Québec). Formulary Update. 2021. Available at: https://www.ramq.gouv.qc.ca/SiteCollectionDocuments/professionnels/
medicaments/codes-medicaments-exception/codes_medicaments_exception.pdf. Retrieved August 24, 2021.
* Comparative clinical signifi cance unknown.
®
† MYRBETRIQ is eligible for formulary coverage with special authorization in Alberta, Saskatchewan, Manitoba, Ontario, Quebec 3‡ , New Brunswick, Newfoundland and Labrador, Nova Scotia, PEI and the NIHB.
Please refer to the respective formularies for coverage information.
‡ GU code 178, for treatment of vesical hyperactivity in persons for whom at least one of the antimuscarinic agents indicated in the regular section of the List is poorly tolerated,
contraindicated or ineffective. Refer to listing for regular section of the List.
®
# A 1-year, randomized, fi xed-dose, double-blind, active-controlled safety study in patients with OAB in which MYRBETRIQ was evaluated for safety in 1,632 patients
®
who received MYRBETRIQ 50 mg OD (n=812 patients) or MYRBETRIQ ® 100 mg (n=820 patients); the 100 mg strength is not available in Canada.
®
Patients received MYRBETRIQ continuously for at least 6 months (n=1,385), 9 months (n=1,311) or 1 year (n=564).
MYRBETRIQ ® is a trademark of Astellas Pharma Canada, Inc. BET_2021_0188_CA_EN